The recall of the Duloxetine Delayed-Release Capsules, produced by Towa Pharmaceutical Europe, was initiated on October 10 and has been given the second highest risk classification by the FDA.
Duloxetine is the first drug to gain FDA approval for the indication of diabetic peripheral neuropathic pain. However, randomized controlled clinical trials of duloxetine for this indication ...
DSM-Firmenich says the FDA is expected to decide within the next 17.5 months — by March 2026 — on the company's request to approve the sunscreen ingredient bemotrizinol, branded as PARSOL Shield.
Some results have been hidden because they may be inaccessible to you